Cancer

Main Content

AIM2CERV

Study title

Phase 3 study of ADXS11-001 administered following chemoradiation as adjuvant treatment for high risk locally advanced cervical cancer

  • Principal Investigator: Dr. Kelly Wilkinson

Purpose

This study is to determine whether an experimental immunotherapy can reduce the rate of recurrence of cervical cancer in women with high-risk locally advanced disease.

Who can participate

Those eligible to participate in this study include:

  • Women 18 years and older with a diagnosis of high risk locally advanced cervical cancer

For more information

  • Sandra Powe
    University of Mississippi Medical Center
    2500 N. State St.
    Jackson MS 39216
    (601) 984-1965
  • IRB Number: 2017-0203